IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Study of HIV-Disease Development in Aging
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to better understand the relationship between age and HIV disease progression.
This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Lopinavir/Ritonavir Drug: Emtricitabine Drug: Stavudine | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging |
| Estimated Enrollment: | 90 |
| Study Start Date: | October 2000 |
| Study Completion Date: | April 2005 |
Older age is an important risk factor for accelerated HIV-disease progression. However, the virologic response to highly active antiretroviral therapy (HAART) may be superior in older persons. A better understanding of the immunologic, virologic, and behavioral mechanisms that underlie these age-related differences may help to elucidate critical immune responses that are necessary to control the progression of HIV-disease.
Patients are grouped according to age. Group A consists of patients between the ages of 13 and 30 years. Group B consists of patients age 45 years or older. All patients receive open-label lopinavir/ritonavir (LPV/RTV) plus emtricitabine (FTC) plus stavudine (d4T) for 96 [AS PER AMENDMENT 06/04/02: 192] weeks. Study visits occur at pre-entry, entry, and Weeks 4, 8, 12, 16, and 24 then every 12 weeks thereafter through Week 96 [AS PER AMENDMENT 06/04/02: Week 192]. Clinical assessments, safety laboratory tests, CD4 cell count monitoring, lymphocyte phenotyping, and HIV-1 RNA determinations are performed routinely. Blood samples are stored for further immunology and virology studies. Patients may volunteer to participate in virology substudy A5020s and either immunology substudy A5016s or A5017s [AS PER AMENDMENT 06/04/02: Substudy A5017s has been eliminated.]
Eligibility| Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
- Are HIV-positive.
- Are between 13 and 30 years old (need consent of parent or guardian if under 18), or are more than 44 years of age.
- Have a viral load of more than 2000 copies/ml within 60 days of study entry.
- Have a CD4 cell count of less than 600 cells/mm3 within 60 days of study entry. (This reflects a change in the CD4 cell count requirement.)
- Agree to use effective methods of birth control (such as condoms) during and for 12 weeks after the study.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Are pregnant or breast-feeding.
- Have an AIDS-related cancer (except Kaposi's sarcoma) requiring chemotherapy.
- Have hepatitis within 30 days of study entry.
- Have diarrhea (more than 3 liquid stools/day for at least 14 days) within 30 days of study entry.
- Are receiving chemotherapy or radiation treatment.
- Have taken antiretroviral drugs for more than 14 days.
- Have received an HIV vaccine within 30 days of study.
- Have a serious illness or infection within 14 days of the study.
- Have other serious conditions that might interfere with study participation.
- Have taken or plan to take certain other drugs that might affect the study results.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00006144
Show 45 Study Locations
| Study Chair: | Robert Kalayjian | |
| Study Chair: | Michael Lederman | |
| Study Chair: | Richard Pollard |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00006144 History of Changes |
| Other Study ID Numbers: |
A5015 10168 ( Registry Identifier: DAIDS ES ) ACTG A5015 AACTG A5015 Substudy ACTG A5016s Substudy ACTG A5020s |
| Study First Received: | August 7, 2000 |
| Last Updated: | November 6, 2013 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Drug Therapy, Combination Stavudine HIV Protease Inhibitors Cohort Studies Ritonavir Disease Progression |
Antigens, CD Reverse Transcriptase Inhibitors Anti-HIV Agents Immunophenotyping Deoxycytidine |
Additional relevant MeSH terms:
|
HIV Infections Disease Progression Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Disease Attributes Pathologic Processes Slow Virus Diseases Ritonavir |
Lopinavir Emtricitabine Stavudine HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on August 16, 2017